ATLANTA, Jan. 27, 2011 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release data from the final readout of the FAME Study after the market close on Thursday, February 3, 2011. The FAME Study consists of two 36-month Phase 3 pivotal clinical trials to assess the safety and efficacy of ILUVIEN® in the treatment of diabetic macular edema (DME).
Alimera will host a conference call and slide show presentation at 4:30 PM ET on February 3, 2011 to discuss the results. The conference call will be hosted by Dan Myers, President and Chief Executive Officer, Ken Green, Chief Scientific Officer and Rick Eiswirth, Chief Operating Officer and Chief Financial Officer.
To participate in the call, please dial (877) 369-6586 (U.S. and Canada) or (253) 237-1165 (international). A live webcast and slide presentation will be available on the Investor Relations section of the corporate website at .
A replay of the conference call will be available beginning February 3, 2011 at 7:30 PM ET and ending on February 10, 2011 by dialing (800) 642-1687 (U.S. and Canada) or (706) 645-9291 (international), Conference ID Number: 40417927.
About Alimera Sciences, Inc.
Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently, the Company is focused on diseases affecting the back of the eye, or retina. Its advanced product candidate, ILUVIEN®, is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. ILUVIEN® is in development for the treatment of diabetic macular edema (DME), a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. A New Drug Application for ILUVIEN® is currently under review by the US Food and Drug Administration.
CONTACT: ICR, LLC for Alimera Sciences John Mills 310-954-1105 John.Mills@icrinc.com